Page 4 - 2021 Spring CMTA Report - Special Research Edition
P. 4

BUILDING









        AND PAYING


       FOR A STAR











        When CMTA Board Chair Gilles Bouchard started getting involved
        with the organization 11 years ago, he found the world of CMT

        research depressing: Some great researchers were working

        on CMT, but because there were no pharmaceutical companies
        involved, the research wasn’t being translated to treatments.












                                                                      $17 MILLION

                                                                      SINCE 2008
                          Research tools for
                           biotech companies









              More than 30 of the leading CMT
            scientists and gene therapy experts           Investments in the discovery of new geneS






                          50 active research
                              projects


                                                               19 joint preclinical treatment studies





    4
   1   2   3   4   5   6   7   8   9